Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960–1999 and registered in the Italian Off-Therapy Registry

Bagnasco, Francesca; Caruso, Silvia; Andreano, Anita; Valsecchi, Maria Grazia; Jankovic, Momcilo; Biondi, Andrea; Miligi, Lucia; Casella, Claudia; Terenziani, Monica; Massimino, Maura; Sacerdote, Carlotta; Morsellino, Vera; Erminio, Giovanni; Garaventa, Alberto; Faraci, Maura; Micalizzi, Concetta; Garrè, Maria Luisa; Pillon, Marta; Basso, Giuseppe; Biasin, Eleonora; Rondelli, Roberto; Pession, Andrea; Locatelli, Franco; Santoro, Nicola; Indolfi, Paolo; Palumbo, Giovanna; Russo, Giovanna; Verzegnassi, Federico; Favre, Claudio; Zecca, Marco; Mura, Rossella; D’Angelo, Paolo; Cano, Carmen; Byrne, Julianne; Haupt, Riccardo; Pierani, Paolo; Pession, A; Porta, Fulvio; Consarino, Caterina; Burnelli, Roberta; Fedeli, Fausto; Cellini, Monica; Casale, Fiorina; Menna, Giuseppe; Bertolini, Patrizia; Caniglia, Maurizio; Cecinati, Valerio; Casazza, Gabriella; Foà, Roberto; Clerico, Aldo; Ladogana, Saverio; Galimberti, Daniela; Rabusin, Marco; Nespoli, Luigi; Cesaro, Simone

doi:10.1016/j.ejca.2018.12.021

Cited by 41 publications

(61 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiovascular diseases after cancer relapse and second malignant neoplasms (SMN) are the leading cause of morbidity and mortality in survivors of childhood cancer and are largely related to therapy with anthracyclines, its’ cumulative dose, and the length of follow-up as risk factors [15,16,17,18].…”

Section: Discussionmentioning

confidence: 99%

Health Status in Long-Term Survivors of Hepatoblastoma

Dembowska‐Bagińska

Więckowska

Brożyna

et al. 2019

Cancers

View full text Add to dashboard Cite

The aim of this study was to evaluate the health status of children cured from hepatoblastoma. Forty-five patients with hepatoblastoma treated between 1996–2014 were assessed. The recorded data included sex, age at diagnosis, disease stage, treatment methods, time since diagnosis, and the evaluation of health status domains which included performance status, growth development, hearing, cardiovascular, skeletal, gastrointestinal, genitourinary, neurological, and hematological function. There were 30 boys and 15 girls. The age at diagnosis ranged from one month to 14 years (median one year). At the time of the health status evaluation, the youngest patient was 5.5 years old and the oldest was 21 years of age (median—10 years). All patients were treated according to the Childhood Liver Tumors Strategy Group—SIOPEL recommendations, though they were not active participants of the studies. The median cumulative dose of cisplatin was 520 mg/m2 and 360 mg/m2 for doxorubicin. Thirty-six patients underwent partial hepatectomy, and nine total hepatectomy and liver transplantation. At a median of nine years from diagnosis, 68% of hepatoblastoma survivors had experienced at least one chronic health condition of any grade. The most frequent late complication was ototoxicity (28.8%), and the most serious were second malignancies (6.6%) and cardiomyopathy (4.4%). Conclusion: Survivors of hepatoblastoma are at risk for long-term complications. They require long-term monitoring for late effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Health Status in Long-Term Survivors of Hepatoblastoma

Dembowska‐Bagińska

Więckowska

Brożyna

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…In this largest ever cohort study investigating the risk of SPLs in five-year CCSs, we showed that the risk of developing a SPL remained elevated for at least 20 years from FPN diagnosis and only the risk of SPML is increased and not for SPLL. Due to the collaborative nature of this study, we were able to expand upon previous individual studies from the UK, 8 France, 6 Italy, 23 Nordic countries, 19 and United States 5,20 and overcome their limitations of low statistical power. Indeed, compared to the largest previous study investigating SPL risk in CCSs from the North American Childhood Cancer Survivor Study, 5 we observed three-times the number of SPLs both overall (115 vs. 43) and beyond 15 years from FPN diagnosis (40 vs. 13).…”

Section: Main Findingsmentioning

confidence: 99%

Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup

Allodji

Hawkins

Bright

et al. 2019

European Journal of Cancer

Self Cite

View full text Add to dashboard Cite

PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies (PanCareSurFup); Childhood Cancer Survivor Study (CCSS); standardized incidence ratio (SIR); absolute excess risk (AER); adolescent and young adult (AYA); confidence intervals (CIs); International Classification of Childhood Cancer (ICCC); relative risk (RR); subsequent primary leukemias (SPLs); first primary neoplasm (FPN); subsequent primary myeloid leukemias (SPML) and subsequent primary lymphoid leukemias (SPLL).

show abstract

“…This apparent risk difference for metabolic syndrome further increases the elevated risks for cardiovascular outcomes and endothelial damage from anthracyclines, alkylating agents, and irradiation [8,9]. Consequently, the mortality due to coronary and cerebrovascular disease in long-term survivors is up to 12.7 times higher than in the general population [10][11][12][13]. The fact that metabolic syndrome can be subclinical for many years emphasizes the need for timely identification of metabolic syndrome in survivors and early intervention strategies.…”

Section: Introductionmentioning

confidence: 99%

Metabolic Syndrome Parameters, Determinants, and Biomarkers in Adult Survivors of Childhood Cancer: Protocol for the Dutch Childhood Cancer Survivor Study on Metabolic Syndrome (Dutch LATER METS)

Pluimakers¹,

Fiocco²,

Atteveld³

et al. 2021

JMIR Res Protoc

View full text Add to dashboard Cite

Background Potential late effects of treatment for childhood cancer include adiposity, insulin resistance, dyslipidemia, and hypertension. These risk factors cluster together as metabolic syndrome and increase the risk for development of diabetes mellitus and cardio- and cerebrovascular disease. Knowledge on risk factors, timely diagnosis, and preventive strategies is of importance to prevent cardio- and cerebrovascular complications and improve quality of life. Currently, no national cohort studies on the prevalence and determinants of metabolic syndrome in childhood cancer survivors, including biomarkers and genetic predisposition, are available. Objective The objectives of the Dutch LATER METS study are to assess 1) the prevalence and risk factors of metabolic syndrome and its separate components, and 2) the potential diagnostic and predictive value of additional biomarkers for surveillance of metabolic syndrome in the national cohort of adult long-term survivors of childhood cancer. Methods This is a cross-sectional study based on recruitment of all survivors treated in the Netherlands between 1963 and 2002. Metabolic syndrome will be classified according to the definitions of the third Adult Treatment Panel Report of the National Cholesterol Education Program as well as the Joint Interim Statement and compared to reference data. Dual-energy x-ray absorptiometry scans were performed to assess body composition in more detail. The effect of patient characteristics, previous treatment, and genetic variation on the risk of metabolic syndrome will be assessed. The diagnostic and predictive value of novel biomarkers will be tested. Results Patient accrual started in 2016 and lasted until April 2020. A total of 2380 survivors from 7 pediatric oncology hospitals have participated. From July 2020, biomarker testing, single nucleotide polymorphism analysis, and data analysis will be performed. Conclusions The Dutch LATER METS study will provide knowledge on clinical and genetic determinants of metabolic syndrome and the diagnostic value of biomarkers in childhood cancer survivors. The results of this study will be used to optimize surveillance guidelines for metabolic syndrome in survivors based on enhanced risk stratification and screening strategies. This will improve diagnosis of metabolic syndrome and prevent complications. International Registered Report Identifier (IRRID) DERR1-10.2196/21256

show abstract

Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960–1999 and registered in the Italian Off-Therapy Registry

Cited by 41 publications

References 35 publications

Health Status in Long-Term Survivors of Hepatoblastoma

Health Status in Long-Term Survivors of Hepatoblastoma

Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup

Metabolic Syndrome Parameters, Determinants, and Biomarkers in Adult Survivors of Childhood Cancer: Protocol for the Dutch Childhood Cancer Survivor Study on Metabolic Syndrome (Dutch LATER METS)

Contact Info

Product

Resources

About